Relapsing-Remitting Multiple Sclerosis and Intermediate Uveitis Treated with Natalizumab

Update Item Information
Identifier 20230312_nanos_posters_078
Title Relapsing-Remitting Multiple Sclerosis and Intermediate Uveitis Treated with Natalizumab
Creator Jieun Kang; Tamer Ghanayem; Alexis Flowers; Subramaniam Sriram; Akshay Thomas; Sapna Gangaputra; Shailee Shah
Affiliation (JK) (TG) (SS) (SS) Vanderbilt University Medical Center; (AF) (SG) Vanderbilt Eye institute; (AT) Tennessee Retina
Subject Neuro-ophth & Systemic Disease (eg. MS, MG, Thyroid); Demeylinating Disease
Description Natalizumab is a disease-modifying therapy (DMT) efficacious in relapsing-remitting multiple sclerosis (RRMS)[1]. Intermediate uveitis is found to coexist with RRMS at higher rates than the general population and often requires prolonged high-dose steroids[2] or immunomodulatory therapy. We report a series of three patients with RRMS and concomitant uveitis effectively treated with natalizumab.
Date 2023-03-14
Language eng
Format application/pdf
Type Text
Source 2023 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS Annual Meeting 2023: Poster Session I: Neuro-Ophthalmic Disorders of Neurologic and Systemic Diseases
Collection Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Rights Management Copyright 2023. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s6gmkdjw
Setname ehsl_novel_nam
ID 2335284
Reference URL https://collections.lib.utah.edu/ark:/87278/s6gmkdjw
Back to Search Results